Subject Characteristics
TNBC, melanoma, tumor
TUMOR, MELANOMA, METASTATIC MELANOMA
Between February 2017 and April 2019, 77 patients (38 with TNBC; 39 with melanoma) were consented for prescreening of tumor tissue for quantification of cMET expression. Of all screened subjects, 47 had cMET testing of a metastatic site, 28 had cMET testing on a primary site, and 1 subject had cMET testing performed on both a primary and metastatic site. Median cMET expression was 35% (range: 0%–100%) for the 38 subjects with TNBC and 10% (range: 0%–100%) for the 39 subjects with metastatic melanoma. Ultimately 37 (48%) of 77 prescreened subjects including 20 (53%) patients with TNBC and 17 (44%) patients with melanoma had ≥30% cMET expression by IHC. Of these patients, 4 individuals with TNBC and 3 individuals with melanoma consented and were treated on study.Characteristics of the 7 subjects enrolled on the therapeutic portion of the study are shown in Patient population